Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma.
BACKGROUND
Prolonged treatment with antiprogestin results in shrinkage of benign uterine leiomyomata. Leiomyomata and uterine leiomyosarcomas share some common features, and they both often express progesterone receptors. Thus, treatment of uterine leiomyosarcomas with antiprogestins has been suggested.


METHODS
The antiprogestin mifepristone was administered (50-200 mg/d) to three patients with recurrent uterine leiomyosarcomas. A dramatic response lasting more than 3 years was observed in a case of recurrent low-grade (G1) progesterone receptor-positive leiomyosarcomas. In two other patients, with G3 leiomyosarcomas, the disease progressed despite several months of mifepristone therapy.


CONCLUSIONS
We speculate that mifepristone has a role in the management of some cases of recurrent uterine leiomyosarcomas.
Koivisto-Korander
Riitta
R
Department of Obstetrics and Gynecology, University of Helsinki, Finland.
Leminen
Arto
A
Heikinheimo
Oskari
O
D003937:Diagnosis, Differential; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007890:Leiomyosarcoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011859:Radiography; D011980:Receptors, Progesterone; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology
D006727:Hormone Antagonists; D011980:Receptors, Progesterone; D015735:Mifepristone